As of November 6, 2026, Myomo, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 16, 2026 to May 13, 2026, naming 2 appointments. The latest filing names William J. Febbo, appointed (Form 8-K, May 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Myomo, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Myomo, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-16 to 2026-05-13. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Myomo, Inc. files it.
Also on the record for Myomo, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 12, 2026 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13D/A, by Horton Capital Partners, LLC | 6% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
| December 29, 2025 | Stake report, Schedule 13D, by Horton Capital Partners, LLC | 5.1% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13G/A, by Orin Hirschman | 1.3% of the class | 5%+ stakes | Source |
| August 11, 2025 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Myomo, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Myomo, Inc. and the records around it.
Myomo, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Horton Capital Partners Fund, LP also filed stake reports on 1 other company: KORU Medical Systems, Inc. (Feb 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
Watch Myomo, Inc.
Get an email when Myomo, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Myomo, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Myomo, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Myomo, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-13 | Reported | not named in the filing | 8-K, 2026-05-13 | ||
| 2026-04-16 | In | 2026-04-14 | 8-K, 2026-04-16 | ||
| 2026-04-16 | In | Director | 8-K, 2026-04-16 |
Who leads Myomo, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: William J. Febbo, appointed (filed 2026-04-16).
New leaders reset buying decisions — get the Full Report on Myomo, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Myomo, Inc., with the record behind each one.
Find candidates like Director at Myomo, Inc.Every change, in the filing's words
Reported
On May 9, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Myomo, Inc. (the "Company"), the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.
- Mr. Manko will serve as a Class I director until his term expires at the 2027 annual meeting of shareholders, at which time he will stand for election by the Company's shareholders.
- Mr. Manko has not been appointed to serve on any committees of the Board.
- Mr. Manko, 60, is currently the Senior Principal of Horton Capital Management LLC ("Horton Fund"), which he founded in 2013 and is a significant shareholder in the Company.
- Previous to his experience with Horton Fund, Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited from 2005 to 2010, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm's Special Situations and Event-Driven strategies.
- Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London.
- He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP.
- Mr. Manko has served on the boards of several companies in the med-tech and bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries.
Appointed: William J. Febbo, effective 2026-04-14
On April 14, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Myomo, Inc. (the "Company"), the Board appointed William J. Febbo to join the Board, effective on April 14, 2026.
Appointed: William J. Febbo, Director
Mr. Febbo will serve as a Class II director until his term expires at the 2028 annual meeting of shareholders, at which time he will stand for election by the Company's shareholders.
- Mr Febbo has not been appointed to serve on any committees of the Board.
- Mr. Febbo, 57, currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately-held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026.
- Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024.
- Mr. Febbo has also co-founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network.
- Mr. Febbo holds a BA in International Studies and Spanish from Dickinson College.
- He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges.
- He also serves as a Mentor for the X & Y Class at Harvard Business School.
- In connection with his appointment to the Board, Mr. Febbo was granted 45,000 restricted stock units ("RSUs"), which will vest in their entirety on the first anniversary of the effective date of his appointment to the Board.
- As a non-employee director, Mr. Febbo will also receive an annual cash retainer of $60,000.
Tools for this story
Each opens in a new tab, filled in for Myomo, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.